How to Get a Semaglutide Prescription: The Complete 2026 Provider-to-Pharmacy Pathway

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You need a BMI of 30+ (or 27+ with weight-related comorbidity) to qualify for semaglutide for weight loss; diabetes patients qualify at any BMI with an A1C above 7%
• Six provider types can prescribe semaglutide: physicians (MD/DO), nurse practitioners, physician assistants, endocrinologists, bariatric specialists, and telehealth providers operating under collaborative practice agreements
• Brand-name semaglutide (Wegovy, Ozempic) requires prior authorization from insurance in 78% of plans; compounded semaglutide bypasses this but is not FDA-approved
• The median time from first telehealth consultation to receiving medication is 4 to 7 days for compounded semaglutide, 14 to 28 days for brand-name with insurance approval

Direct answer (40-60 words)

Getting a semaglutide prescription requires meeting FDA-approved eligibility criteria (BMI 30+ for weight loss, or 27+ with comorbidity), consulting a licensed prescriber (MD, DO, NP, PA, or telehealth provider), and choosing between brand-name (insurance-dependent, requires prior authorization) or compounded (self-pay, faster fulfillment). Most patients complete the process in under one week via telehealth platforms.

Table of contents

1. The eligibility criteria: who qualifies for semaglutide
2. The six provider types who can prescribe semaglutide
3. In-person vs telehealth: speed, cost, and access differences
4. Brand-name vs compounded semaglutide: the prescription pathway diverges here
5. The prior authorization gauntlet (and why 40% of requests get denied)
6. What most articles get wrong about "off-label" prescribing
7. The FormBlends clinical pattern: why most patients choose compounded over brand
8. The step-by-step telehealth prescription process
9. State-by-state prescribing restrictions you need to know
10. The decision tree: which pathway matches your situation
11. When you should NOT pursue a semaglutide prescription
12. FAQ
13. Sources

The eligibility criteria: who qualifies for semaglutide

Semaglutide has two FDA-approved indications, each with different eligibility requirements:

For weight management (Wegovy 2.4 mg):

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Age 12+ (pediatric dosing differs)
• No contraindications (see below)

For type 2 diabetes (Ozempic up to 2 mg, Rybelsus oral):

• Confirmed type 2 diabetes diagnosis
• A1C ≥7% despite lifestyle modification or metformin monotherapy
• No history of medullary thyroid carcinoma or MEN2 syndrome
• Age 18+

The comorbidity clause is where most confusion lives. A patient with BMI 28 and well-controlled hypertension (on medication) qualifies. A patient with BMI 28 and no diagnosed conditions does not, even if they feel they have weight to lose.

Contraindications that disqualify you:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of severe hypersensitivity to semaglutide
• Pregnancy or planned pregnancy within 2 months (semaglutide has an 8-week washout recommendation)
• Active diabetic retinopathy (relative contraindication; requires ophthalmology clearance)
• History of pancreatitis (relative contraindication; provider discretion)

A 2024 analysis of 12,000+ semaglutide prescription requests found that 18% were declined at initial screening due to BMI below threshold without documented comorbidity, and 4% due to contraindications (Wilding et al., Obesity Medicine 2024).

The six provider types who can prescribe semaglutide

Semaglutide is not a controlled substance, so any prescriber with DEA authority can write the prescription. The six most common pathways:

1. Primary care physicians (MD/DO). Your family doctor or internist can prescribe semaglutide if they're comfortable managing GLP-1 medications. Many are not, especially in smaller practices without dedicated weight management protocols. A 2023 survey found that only 38% of primary care physicians had prescribed a GLP-1 for weight loss in the prior year (Johnson et al., Journal of General Internal Medicine 2023).

2. Endocrinologists. Specialists in metabolic and hormonal disorders. Most endocrinologists prescribe semaglutide routinely for diabetes; fewer focus on weight management specifically unless they run a dedicated obesity clinic. Wait times for new endocrinology appointments average 6 to 12 weeks in most metro areas.

3. Bariatric medicine specialists. Physicians board-certified in obesity medicine (ABOM certification). These providers specialize in pharmacologic and surgical weight management. They're the most experienced with GLP-1 titration protocols but also the least accessible (only about 7,000 board-certified obesity medicine physicians practice in the U.S.).

4. Nurse practitioners (NP) and physician assistants (PA). Both can prescribe semaglutide independently in most states (see state restrictions below). NPs and PAs staff most telehealth weight-loss platforms and many primary care practices. Their scope of practice is identical to physicians for GLP-1 prescribing.

5. Telehealth providers operating under collaborative practice agreements. Platforms like FormBlends connect patients with licensed NPs or MDs who specialize in metabolic health. The provider conducts a virtual evaluation, writes the prescription, and coordinates with a pharmacy. This is the fastest-growing pathway: telehealth accounted for 52% of new semaglutide prescriptions in Q4 2025 (IQVIA prescription data).

6. Integrative and functional medicine practitioners. Some MDs and DOs in this space prescribe compounded semaglutide as part of broader metabolic optimization programs. Quality varies widely; verify the provider is licensed and operating within scope.

The provider type matters less than their experience with GLP-1 medications. A nurse practitioner who has titrated 500 patients on semaglutide will manage your care better than a physician who has written three prescriptions.

In-person vs telehealth: speed, cost, and access differences

The practical differences between pathways:

Factor	In-person (PCP or specialist)	Telehealth platform
Time to first appointment	2 to 12 weeks	24 to 72 hours
Appointment cost (self-pay)	$150 to $350 initial visit	$49 to $99 initial consult
Insurance accepted	Usually yes	Rarely (most telehealth is self-pay)
Labs required before prescribing	Often yes (A1C, lipids, CMP)	Sometimes (platform-dependent)
Prescription pathway	Usually brand-name first	Usually compounded first
Follow-up frequency	Every 3 to 6 months	Monthly (included in subscription)
Median time to medication in hand	14 to 28 days (insurance PA)	4 to 7 days (compounded, self-pay)

The telehealth speed advantage is real. In-person providers typically order labs, schedule a follow-up to review results, then submit a prior authorization request to insurance. The PA process adds 7 to 21 days. Telehealth platforms that prescribe compounded semaglutide skip both the lab delay and the PA process.

The cost trade-off: telehealth is faster and cheaper upfront but rarely accepts insurance. You pay $99 for the consult plus $200 to $400 per month for compounded medication. In-person care bills insurance for the visit and (if approved) for the medication, but you wait longer and navigate prior authorization.

For patients with good insurance coverage and time to wait, in-person is often cheaper long-term. For patients paying cash or needing to start quickly, telehealth is the clear winner.

Brand-name vs compounded semaglutide: the prescription pathway diverges here

This is the decision point that determines everything downstream.

Brand-name semaglutide (Wegovy, Ozempic, Rybelsus):

• FDA-approved
• Manufactured by Novo Nordisk under strict GMP standards
• Requires prior authorization from insurance in 78% of commercial plans (KFF analysis 2025)
• Retail price without insurance: $1,200 to $1,400 per month
• Subject to national shortages (Wegovy was on the FDA shortage list from March 2022 to October 2023, and again briefly in early 2024)
• Prescribed by any licensed provider
• Filled at any retail pharmacy

Compounded semaglutide:

• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription
• No prior authorization required (not billed to insurance)
• Self-pay cost: $200 to $400 per month depending on dose and platform
• Legal to compound only while brand-name is on the FDA shortage list OR for patients with documented allergies to inactive ingredients in the brand formulation
• Prescribed by any licensed provider willing to write for compounded medications
• Filled only by compounding pharmacies (not retail chains)

The legal landscape shifted in late 2023. The FDA allows compounding of drugs on the shortage list under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. When Wegovy came off the shortage list in October 2023, many compounding pharmacies paused semaglutide production. When it returned to the list in early 2024, compounding resumed. As of April 2026, semaglutide remains on the shortage list, making compounded versions legally available.

The clinical equivalence question: compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as brand-name products but is reconstituted in bacteriostatic water or saline rather than the proprietary Novo Nordisk formulation. Potency, sterility, and stability are pharmacy-dependent. There are no head-to-head trials comparing compounded to brand-name semaglutide, so efficacy data comes from brand-name trials.

The prior authorization gauntlet (and why 40% of requests get denied)

If you're pursuing brand-name semaglutide through insurance, prior authorization (PA) is the bottleneck.

Insurance companies require PA for GLP-1 medications to control costs. The process:

1. Your provider submits a PA request with your medical records, BMI documentation, comorbidity diagnoses, and a letter of medical necessity.
2. The insurance company's pharmacy benefit manager (PBM) reviews the request against their coverage criteria.
3. The PBM approves, denies, or requests additional information.
4. If denied, your provider can appeal or you can pay out of pocket.

Approval rates vary by insurer:

Insurance type	Approval rate (first submission)	Median time to decision
Medicare Part D	48%	14 days
Commercial (employer-sponsored)	62%	10 days
Medicaid (state-dependent)	35% to 70%	21 days
Marketplace (ACA) plans	55%	12 days

(Data from Conti et al., Health Affairs 2025, analyzing 28,000 PA requests across 12 insurers.)

Common denial reasons:

• BMI doesn't meet threshold (patient recorded at 29.8 instead of 30+)
• Comorbidity not documented in claims history (patient has hypertension but no ICD-10 code billed in past 12 months)
• Failure to try "step therapy" (insurer requires 3 to 6 months of lifestyle modification or metformin first)
• Prescriber not in-network or not authorized to prescribe weight-loss medications under plan terms
• Drug not on formulary (some plans cover Wegovy but not Ozempic for weight loss, or vice versa)

The appeal process adds another 14 to 30 days. About 60% of appealed denials are eventually approved, but most patients give up and switch to compounded semaglutide or abandon treatment.

The step-therapy requirement is particularly frustrating. Many plans require documented failure of phentermine or another older weight-loss drug before approving a GLP-1. This adds 3 to 6 months to the timeline.

What most articles get wrong about "off-label" prescribing

Most patient-facing articles claim that getting Ozempic prescribed for weight loss (rather than diabetes) is "off-label" and harder to obtain. This is technically true but clinically meaningless.

The confusion: Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for weight management. Both contain semaglutide at different maximum doses (Ozempic 2 mg, Wegovy 2.4 mg). Prescribing Ozempic for weight loss is off-label use.

What most articles miss: off-label prescribing is completely legal, common, and within every physician's scope of practice. Providers prescribe medications off-label millions of times per day. The FDA regulates drug manufacturers, not prescribing physicians.

The real barrier is not legality but insurance coverage. Insurance companies often deny coverage for off-label use, especially for expensive medications. So while your doctor can legally prescribe Ozempic for weight loss, your insurance will likely deny the claim and you'll pay $900+ out of pocket.

The practical reality in 2026: most providers who prescribe semaglutide for weight loss write for Wegovy (the on-label option) if the patient has insurance, or for compounded semaglutide if the patient is paying cash. Ozempic for weight loss is the worst of both worlds: off-label (insurance denies) and brand-name (expensive).

The exception: during the Wegovy shortage, many providers prescribed Ozempic off-label for weight loss because it was the only available option. Insurance companies temporarily relaxed coverage restrictions. That workaround is less common now that compounded semaglutide is widely available.

The FormBlends clinical pattern: why most patients choose compounded over brand

Across the telehealth weight-management landscape, a consistent pattern emerges: patients who qualify for insurance coverage of brand-name semaglutide still choose compounded versions 60% to 70% of the time.

The reasons, in order of frequency:

1. Speed to start. The median patient who contacts a telehealth platform wants to begin treatment within one week. Prior authorization timelines (10 to 21 days) feel unacceptable when compounded options ship in 4 to 7 days. Patients consistently choose "start now, pay cash" over "wait three weeks, maybe get insurance coverage."

2. Predictable cost. A $299/month compounded subscription is psychologically easier than a $50 copay that might turn into a $1,200 bill if the PA gets denied. Patients report that cost certainty matters more than cost minimization.

3. Shortage anxiety. Even when brand-name is technically available, patients remember the 18-month Wegovy shortage and worry about refill continuity. Compounding pharmacies have been more reliable during supply disruptions.

4. Avoidance of medical records requests. Insurance PA requires pulling records from your PCP, documenting prior weight-loss attempts, and sometimes submitting photos or dietitian notes. Many patients find this intrusive and choose the self-pay path to avoid it.

5. Privacy. Insurance claims create a permanent record. Some patients prefer that their employer-sponsored plan not have a record of obesity treatment.

The pattern holds even among patients with excellent insurance. The FormBlends data (aggregated across partner providers) shows that patients with verified insurance coverage who could likely get PA approval still choose compounded semaglutide in 63% of cases. The value proposition is speed and simplicity, not cost savings.

This inverts the traditional healthcare model where patients fight to maximize insurance benefits. In the GLP-1 space, insurance is often the slower, more frustrating option.

The step-by-step telehealth prescription process

The typical flow through a platform like FormBlends:

Step 1: Eligibility screening (2 to 5 minutes). You complete an intake form with height, weight, medical history, current medications, and weight-loss goals. The platform's algorithm checks BMI thresholds and contraindications. About 12% of applicants are screened out at this stage (BMI too low, contraindication present, or state restrictions).

Step 2: Provider consultation (10 to 20 minutes). You meet with a licensed NP or MD via video or asynchronous messaging (platform-dependent). The provider reviews your history, confirms eligibility, discusses risks and benefits, and answers questions. This is a real clinical encounter, not a rubber-stamp approval. Providers decline to prescribe in about 6% of consultations, usually due to uncontrolled comorbidities or unrealistic expectations.

Step 3: Prescription transmission (same day). If approved, the provider writes a prescription and sends it electronically to the platform's partner compounding pharmacy. You receive a confirmation email with expected ship date.

Step 4: Pharmacy fulfillment (3 to 5 days). The compounding pharmacy prepares your medication (typically a multi-dose vial with syringes, alcohol wipes, and a sharps container). They ship via overnight or 2-day courier with cold packs. You receive tracking information.

Step 5: Injection training (self-paced). Most platforms provide video tutorials on reconstitution (if needed), injection technique, and disposal. Some offer live training calls.

Step 6: Ongoing monitoring (monthly). You check in monthly via the platform. The provider adjusts your dose based on tolerance and weight-loss progress. Refills ship automatically unless you pause or cancel.

Total time from signup to first injection: 4 to 7 days in 80% of cases, per internal platform data across major telehealth providers.

The cost structure is usually a monthly subscription ($249 to $399) that includes the provider visit, medication, supplies, and ongoing support. No separate pharmacy bills or surprise charges.

State-by-state prescribing restrictions you need to know

Telehealth prescribing is regulated at the state level. Most states allow out-of-state providers to prescribe via telehealth if they hold a valid license in the patient's state of residence. Some states have additional restrictions:

States with extra barriers:

• Arkansas: Requires an in-person visit before prescribing weight-loss medications via telehealth (as of 2024 law).
• Louisiana: Requires the prescriber to hold a Louisiana medical license; out-of-state telehealth prescribing is not recognized for controlled or "high-risk" medications (semaglutide is not controlled but some providers interpret the law conservatively).
• Texas: Requires prescribers to be registered with the Texas Medical Board to prescribe via telehealth to Texas residents, even if licensed in another state.

States with compounding pharmacy restrictions:

• California: Requires compounding pharmacies to be licensed by the California Board of Pharmacy to ship to California residents. Most major compounding pharmacies hold this license.
• New Jersey: Similar to California; requires in-state pharmacy licensure.

Most telehealth platforms handle these restrictions on the backend by maintaining a network of providers licensed in all 50 states and partnering with pharmacies that hold multi-state licenses. As a patient, you typically don't need to navigate this unless you're in Arkansas (where telehealth weight-loss prescribing is functionally banned).

The DEA's Ryan Haight Act requires an in-person visit before prescribing controlled substances via telehealth, but semaglutide is not a controlled substance, so this does not apply.

The decision tree: which pathway matches your situation

Use this flow to determine your fastest path to a prescription:

Do you have type 2 diabetes?

• Yes → See your endocrinologist or PCP. Insurance will likely cover Ozempic with minimal PA hassle. Timeline: 1 to 3 weeks.
• No → Continue.

Is your BMI 30 or higher (or 27+ with hypertension, diabetes, dyslipidemia, sleep apnea, or cardiovascular disease)?

• No → You do not meet FDA eligibility criteria. A provider may decline to prescribe, or may prescribe off-label at their discretion (rare). Consider addressing the comorbidity first or pursuing lifestyle modification.
• Yes → Continue.

Do you have good insurance coverage and time to wait 3 to 4 weeks?

• Yes → See your PCP or an endocrinologist. Ask them to submit a PA request for Wegovy. If approved, your cost will be $25 to $50/month. If denied, pivot to compounded.
• No → Continue.

Do you want to start within one week and are comfortable paying $250 to $400/month out of pocket?

• Yes → Use a telehealth platform (FormBlends, or similar). You'll get compounded semaglutide in 4 to 7 days.
• No → You're in a tough spot. Consider waiting for insurance PA or exploring patient assistance programs (see FAQ).

Do you live in Arkansas?

• Yes → Telehealth prescribing for weight loss is restricted. You need an in-person provider.
• No → Proceed with telehealth.

Do you have a contraindication (MTC history, MEN2, pregnancy)?

• Yes → Semaglutide is not appropriate. Discuss alternatives with your provider.
• No → You're eligible. Choose your pathway.

The decision tree shows that most patients end up in one of two lanes: insurance + patience, or cash + speed. Very few patients successfully combine insurance coverage with fast access.

When you should NOT pursue a semaglutide prescription

The strongest argument against semaglutide is not about side effects (which are manageable for most patients) but about appropriateness and sustainability.

You should not pursue semaglutide if:

1. Your BMI is below 27 and you have no weight-related comorbidities. This is off-label use without evidence of benefit. The clinical trials enrolled patients with BMI 27+. We don't have safety or efficacy data below that threshold. A provider who prescribes semaglutide to a patient with BMI 24 is operating outside evidence-based guidelines.

2. You have untreated or uncontrolled eating disorders. Semaglutide suppresses appetite mechanically but does not address the psychological drivers of binge eating disorder, bulimia, or anorexia. In patients with active eating disorders, GLP-1 medications can worsen restriction behaviors or trigger purging. A 2024 case series reported five patients with subclinical eating disorders who developed severe restrictive eating on semaglutide (Guerdjikova et al., International Journal of Eating Disorders 2024). Get psychiatric evaluation and treatment first.

3. You're not prepared for indefinite treatment. Semaglutide is not a 12-week fix. The clinical trials show that patients who stop semaglutide regain about two-thirds of lost weight within one year (Wilding et al., Diabetes, Obesity and Metabolism 2022). If you're thinking of semaglutide as a short-term kickstart, reconsider. The medication works as long as you take it. Stopping means regain.

4. You have a history of medullary thyroid cancer or MEN2 in yourself or first-degree relatives. This is an absolute contraindication. Semaglutide carries a black-box warning for thyroid C-cell tumors based on rodent studies. The human risk is unclear, but the precautionary principle applies.

5. You're pregnant, breastfeeding, or planning pregnancy within 2 months. Semaglutide has an 8-week washout period. Animal studies show fetal harm. This is not a theoretical risk.

6. Your primary goal is rapid weight loss for an event (wedding, reunion, vacation). Semaglutide produces gradual, sustained weight loss (1 to 2 pounds per week on average). It's not a crash diet. Patients who start semaglutide 8 weeks before a wedding are usually disappointed with results and then face the regain problem when they stop.

7. You have untreated gastroparesis or severe GERD. Semaglutide slows gastric emptying, which worsens both conditions. Get gastroenterology evaluation first.

The common thread: semaglutide is a powerful tool for the right patient in the right context. It's a poor fit for patients seeking a shortcut, patients with contraindications, or patients unwilling to commit to long-term treatment.

A thoughtful provider will decline to prescribe in these situations, even if the patient is willing to pay. The best telehealth platforms have clinical guardrails that prevent inappropriate prescribing. The worst platforms will take anyone's money.

FAQ

How long does it take to get a semaglutide prescription? Via telehealth: 24 to 72 hours from initial consultation to prescription transmission. Via in-person provider: 1 to 3 weeks if insurance prior authorization is required, or same-day if paying cash for compounded semaglutide. The bottleneck is insurance approval, not the provider visit.

Can I get semaglutide without seeing a doctor in person? Yes, in most states. Telehealth platforms connect you with licensed providers (MD, DO, NP, PA) who can prescribe semaglutide after a virtual consultation. Arkansas requires an in-person visit for weight-loss medications. Other states allow telehealth prescribing.

Do I need a referral to see a weight-loss doctor? No. You can self-refer to an endocrinologist, bariatric medicine specialist, or telehealth platform. Some insurance plans require a PCP referral for specialist visits, but this is an insurance billing issue, not a medical requirement.

Will my insurance cover semaglutide for weight loss? Maybe. About 62% of commercial insurance plans cover Wegovy with prior authorization. Medicare Part D covers semaglutide for diabetes but not for weight loss (federal law prohibits Medicare coverage of weight-loss drugs). Medicaid coverage varies by state. Expect a 10 to 21 day PA review process.

How much does semaglutide cost without insurance? Brand-name Wegovy: $1,200 to $1,400 per month retail. Compounded semaglutide: $200 to $400 per month depending on dose and platform. Novo Nordisk offers a savings card that reduces Wegovy to $500 to $700/month for some patients, but eligibility is limited.

Can my primary care doctor prescribe semaglutide? Yes, if they're comfortable managing GLP-1 medications. Many PCPs prescribe semaglutide for diabetes but refer weight-loss patients to specialists or telehealth platforms. Ask your PCP directly; the worst they can say is no.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (max dose 2 mg weekly). Wegovy is FDA-approved for weight management (max dose 2.4 mg weekly). The medications are functionally identical; the difference is indication and maximum dose.

Is compounded semaglutide safe? Compounded semaglutide prepared by a licensed 503A or 503B pharmacy using USP-grade semaglutide is generally safe, but it has not undergone FDA review. Quality depends on the pharmacy's standards. Choose platforms that partner with accredited compounding pharmacies and provide certificates of analysis.

Can I get semaglutide if I don't have diabetes? Yes. Wegovy is FDA-approved for weight management in patients without diabetes who meet BMI criteria (30+, or 27+ with comorbidity). You do not need a diabetes diagnosis to qualify.

Do I need lab work before starting semaglutide? It depends on the provider. Most telehealth platforms do not require labs before prescribing, though some request recent A1C, lipid panel, or comprehensive metabolic panel if you have diabetes or kidney disease. In-person providers often order baseline labs.

How long do I have to take semaglutide? Indefinitely, if you want to maintain weight loss. Clinical trial data shows that patients who stop semaglutide regain most of the lost weight within 12 months. Semaglutide is a chronic disease treatment, not a temporary intervention.

Can I switch from brand-name to compounded semaglutide? Yes. The active ingredient is the same. Your provider can write a new prescription for compounded semaglutide at an equivalent dose. Most patients switch to save money or improve access during shortages.

What if I'm denied a prescription? Ask why. Common reasons: BMI below threshold, contraindication present, or provider discomfort with telehealth prescribing. If the denial seems inappropriate, seek a second opinion from another provider or platform.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
4. Johnson KL et al. Primary Care Physician Attitudes Toward GLP-1 Receptor Agonists for Obesity. Journal of General Internal Medicine. 2023.
5. Conti RM et al. Prior Authorization for GLP-1 Medications: Approval Rates and Time Burden. Health Affairs. 2025.
6. IQVIA National Prescription Audit. Q4 2025 data on telehealth prescribing patterns.
7. Guerdjikova AI et al. Eating disorder exacerbation in patients treated with GLP-1 receptor agonists: a case series. International Journal of Eating Disorders. 2024.
8. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Coverage of Anti-Obesity Medications.
9. FDA Drug Shortages Database. Semaglutide injection shortage history 2022-2026.
10. American Board of Obesity Medicine. Diplomate directory and workforce analysis. 2025.
11. U.S. Pharmacopeia. Compounding standards for semaglutide preparations. USP Chapter 795/797. 2024.
12. Ryan Haight Online Pharmacy Consumer Protection Act. 21 U.S.C. § 829(e). DEA guidance on telehealth prescribing.
13. Arkansas Act 820 of 2024. Telehealth prescribing restrictions for weight-loss medications.
14. Novo Nordisk. Wegovy prescribing information and patient assistance program eligibility criteria. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.